I think its fair value for the short term, if your for long term then you need volume of shares. IMO this stock will recover, over the coming years.
Sydney - Thursday - August 27: (RWE Australian Business News) -
Minara Resources Ltd (ASX:MRE) incurred a $3.1m net loss in the six
months ended June 30, compared with a net profit of $50.9m for the first
half of last year.
Revenue fell 34pc to $190.1m from $289.4m.
Cash on hand at June 30 was $127.2m.
The company remains debt-free with a strong balance sheet.
On an operational basis Minara was cash flow positive for the
six months.
There was a marginal decrease in cash reserves due to the impact
of nickel provisional pricing in the first three months of the year and
increased sulphur stocks bought to take advantage of current low prices.
The board has not declared a dividend for the period.
*****
"Under challenging circumstances Minara delivered a strong
performance over the first six months of the year, posting a small loss
in one of the most difficult periods in the company's history," managing
director and CEO Mr Peter Johnston said.
"We have continued to exercise successful cost reductions at all
levels despite currency fluctuations and a decline in the cobalt market.
"Our targeted capital investment from previous years has ensured
a consistent production profile which will remain the company's focus
throughout 2009.
"The nickel market is slowly recovering, which is reflected in
the current nickel price which has improved in July and August.
"Having achieved a stable production profile with good cash
reserves and a strong balance sheet, Minara is well-positioned to
capitalise on the nickel market recovery," Mr Johnston said.
ENDS rx
Copyright © 2009 RWE Australian Business News. All rights reserved.
- Forums
- ASX - By Stock
- MRE
- Ann: Half Yearly Results
Ann: Half Yearly Results , page-3
Featured News
Add MRE (ASX) to my watchlist
(20min delay)
|
|||||
Last
87.0¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online